Glimepiride
Clinical data | |
---|---|
Trade names | Amaryl, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a696016 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 100% |
Protein binding | >99.5% |
Metabolism | Complete Liver (1st stage through CYP2C9) |
Onset of action | 2–3 hours |
Elimination half-life | 5–8 hours |
Duration of action | 24 hours |
Excretion | Urine (~60%), feces (~40%) |
Identifiers | |
| |
JSmol) | |
Melting point | 207 °C (405 °F) |
| |
| |
(what is this?) (verify) |
Glimepiride is an
Common side effects include headache, nausea, and dizziness.
Glimepiride was patented in 1979 and approved for medical use in 1995.
Medical uses
Glimepiride is indicated to treat type 2 diabetes; its mode of action is to increase insulin secretion by the pancreas. However it requires adequate insulin synthesis as prerequisite to treat appropriately. It is not used for type 1 diabetes because in type 1 diabetes the pancreas is not able to produce insulin.[8]
Contraindications
Its use is contraindicated in patients with hypersensitivity to glimepiride or other sulfonylureas.
Adverse effects
Side effects from taking glimepiride include gastrointestinal tract (GI) disturbances, occasional allergic reactions, and rarely blood production disorders including thrombocytopenia, leukopenia, and hemolytic anemia. In the initial weeks of treatment, the risk of hypoglycemia may be increased. Alcohol consumption and exposure to sunlight should be restricted because they can worsen side effects.[8]
Interactions
Mechanism of action
Like all
Not all secondary sulfonylureas have the same risk of hypoglycemia. Glibenclamide (glyburide) is associated with an incidence of hypoglycemia of up to 20–30%, compared to as low as 2% to 4% with glimepiride. Glibenclamide also interferes with the normal homeostatic suppression of insulin secretion in reaction to hypoglycemia, whereas glimepiride does not. Also, glibenclamide diminishes glucagon secretion in reaction to hypoglycemia, whereas glimepiride does not.[10]
Pharmacokinetics
Gastrointestinal absorption is complete, with no interference from meals. Significant absorption can occur within one hour, and distribution is throughout the body, 99.5% bound to plasma protein. Metabolism is by oxidative biotransformation, it is hepatic and complete. First, the medication is metabolized to M1 metabolite by CYP2C9. M1 possesses about 1⁄3 of pharmacological activity of glimepiride, yet it is unknown if this results in clinically meaningful effect on blood glucose. M1 is further metabolized to M2 metabolite by cytosolic enzymes. M2 is pharmacologically inactive. Excretion in the urine is about 65%, and the remainder is excreted in the feces.
References
- ^ a b c d e f g h "Glimepiride Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ^ ISBN 9780857113382.
- ^ "Glimepiride Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- PMID 15531188.
- ISBN 9783527607495.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Glimepiride - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- ^ a b "Glimepiride: MedlinePlus Drug Information". nih.gov.
- PMID 18378631.
- ISBN 0-07-142280-3.